GlassScriptPhysician profile
Amia Lynn Washington
NPI 1801538913
$1,962.81
in general payments reported to CMS, 2019-2025
21 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $358 · 2023: $845 · 2024: $645 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,604.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.54 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $292.21 | 2022-2024 | Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $146.79 | 2023-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $143.11 | 2022-2024 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.68 | 2022-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $121.05 | 2022-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $87.40 | 2023-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $84.91 | 2023-2024 | Auvelity, Sunosi |
| Tris Pharma INC | $68.34 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Almatica Pharma LLC | $66.87 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $62.66 | 2022-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $54.35 | 2023-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $51.77 | 2022-2023 | Abilify Maintena, Rexulti |
| Indivior INC. | $41.54 | 2023 | Perseris |
| Supernus Pharmaceuticals, INC. | $37.33 | 2022-2023 | Qelbree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $33.06 | 2023-2024 | Ingrezza |
| Corium, LLC | $23.60 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $22.71 | 2022 | |
| Idorsia Pharmaceuticals US INC | $19.59 | 2024 | Quviviq |
| Brainsway USA INC | $17.22 | 2023 | |
| Vertical Pharmaceuticals, LLC | $13.08 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amia Washington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.